Chouhan suggests buying Lupin at the current market price with a stop loss at Rs 1,940 and target price of Rs 2,035.

Axis Securities highlights mid-cap and small-cap stocks as the Indian market recovers. Key recommendations include Lupin and ...

The move is part of Lupin's broader strategy to create a specialised consumer healthcare entity, particularly aimed at ...

This is eligible for 180 days of generic drug exclusivity. The company will manufacture the product at its facility situated ...

Pharmaceutical major Lupin Limited has announced the strategic spin-off of its consumer healthcare business, LupinLife ...

Mumbai: Global pharma major Lupin Limited, has announced the strategic carve-out of its consumer healthcare business, ...

Lupin receives US FDA approval for loteprednol etabonate ophthalmic gel: Our Bureau, Mumbai Wednesday, July 2, 2025, 11:40 Hrs [IST] Global pharma major Lupin Limited (Lupin) anno ...

Lupin launches independent consumer healthcare entity to focus on India's self-care market, led by Anil Kaushal.

The product is a corticosteroid indicated for the treatment of postoperative inflammation and pain following ocular surgery.

Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Lupin Limited (NSEI:LUPIN), with a market capitalization of ₹363.61B, rarely draw their attention ...

Lupin Ltd AGM: Check out the latest updates, dates, and news about the Lupin Ltd AGM at IIFL Capital.

Lupin Limited (NSEI:LUPIN) is trading with a trailing P/E of 138.9x, which is higher than the industry average of 25.3x. While LUPIN might seem like a stock to avoid orRead More ...